Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Nasopharyngeal Carcinoma 26Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Nasopharyngeal Neoplasms 6Head and Neck Neoplasms 6Breast Neoplasms 5Uterine Cervical Neoplasms 4Oropharyngeal Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tongue Neoplasms 2Salivary Gland Neoplasms 2Radiation Injuries 2Neurotoxicity Syndromes 2Hypopharyngeal Neoplasms 2Glioblastoma 2Carcinoma 2Brain Neoplasms 2Astrocytoma 2Vaginal Neoplasms 1Thoracic Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1Sarcoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Pancreatic Intraductal Neoplasms 1Pancreatic Adenocarcinoma 1Ototoxicity 1Oligodendroglioma 1

Interventions

mazdutide 1Tablets 1Sugars 1Standard of Care 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Metformin 1Memantine 1Hormones 1G(M1) Ganglioside 1Exercise 1Donepezil 1Counseling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cognitive Dysfunction × Radiotherapy, Intensity-Modulated × Clear all
NCT02360215 2025-04-23

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NRG Oncology

Phase 3 Completed
518 enrolled 40 charts
CNS

Brain Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡